We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Research Makes Flu Virus Visible to Naked Eye

By LabMedica International staff writers
Posted on 16 May 2017
Researchers have discovered a way to make influenza visible to the naked eye by engineering fluorescent dye molecules to target a specific enzyme of the virus. The team was able to develop a prototype test kit that detects influenza in samples using a handheld lamp or blue laser pointer, and that even helps determine if a given antiviral therapy will likely be effective.

The scientists, from University of Notre Dame, created a new method to detect neuraminidase, which is located on the surface of the virus. They began by designing a dye molecule to emit red fluorescent light when it interacts with the neuraminidase. They then used test samples that mimicked that of an infected patient, and spiked the samples with neuraminidase that had been purified from the virus. Emission of red fluorescent light from a sample is a positive indication of the influenza virus, blue signals a negative result.

Image: Scientists have developed a new way to detect a flu infection through detecting neuraminidase, a spiky enzyme that helps the influenza virus spread to other cells in the body (Photo courtesy of Deposit Photos).
Image: Scientists have developed a new way to detect a flu infection through detecting neuraminidase, a spiky enzyme that helps the influenza virus spread to other cells in the body (Photo courtesy of Deposit Photos).

While still a prototype, with optimization the diagnostic could potentially be developed for use in point-of-care clinics or the home environment for a rapid, easy to interpret test for the presence of influenza.

The same process also allowed them to determine which of two approved antiviral drugs would be a better treatment option for the individual patient.

Following validation of enzyme recognition, the team tested the dye with two antiviral drugs used to treat influenza (Zanamivir, also known as Relenza, and Oseltamivir, known widely as Tamiflu). Both antivirals are neuraminidase inhibitors. Antiviral drug was added to samples containing dye and neuraminidase. Upon illumination, red fluorescence indicated the enzyme was still active, whereas blue indicated the drug failed to inhibit the enzyme. For patient samples, blue fluorescence would indicate the neuraminidase activity had been blocked, presenting an effective treatment option.

“Viral cultures are the gold standard for diagnosis of influenza but take several days to develop. By targeting an enzyme inherent to the virus and identifying its presence in a sample, we can make a rapid determination of the influenza in a patient for an efficient and immediate diagnostic that would improve patient treatment and reduce overuse of antivirals,” said study leader Bradley Smith, professor at Notre Dame.

The study, by Liu W et al, was published April 20, 2017, in the Journal of the American Chemical Society.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Latest Technology News

New Diagnostic System Achieves PCR Testing Accuracy

DNA Biosensor Enables Early Diagnosis of Cervical Cancer

Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples